Systemic Therapy in Hepatocellular Carcinoma

被引：33

作者：

Wrzesinski, Stephen H. ^{[2
,3
]}

Taddei, Tamar H. ^{[1
,4
]}

Strazzabosco, Mario ^{[1
,5
,6
]}

机构：

[1] Yale Univ, Sch Med, Dept Internal Med, Sect Digest Dis, New Haven, CT 06520 USA

[2] Yale Univ, Sch Med, Yale Comprehens Canc Ctr, New Haven, CT 06520 USA

[3] VA Connecticut Healthcare Syst, Ctr Comprehens Canc, West Haven, CT 06516 USA

[4] VA Connecticut Healthcare Syst, HCRC, West Haven, CT 06516 USA

[5] Yale Univ, Yale Liver Ctr, Dept Internal Med, New Haven, CT 06520 USA

[6] Univ Milano Bicocca, Sect Digest Dis, Monza, Italy

来源：

CLINICS IN LIVER DISEASE | 2011年 / 15卷 / 02期

关键词：

Systemic therapy; Chemotherapy; Hepatocellular carcinoma; PHASE-II TRIAL; RANDOMIZED CONTROLLED-TRIAL; ENDOTHELIAL GROWTH-FACTOR; PLUS OXALIPLATIN GEMOX; COMBINATION CHEMOTHERAPY; INTERFERON-ALPHA; FACTOR RECEPTOR; DOXORUBICIN; GEMCITABINE; BEVACIZUMAB;

D O I：

10.1016/j.cld.2011.03.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

100201 [内科学];

摘要：

Many potential systemic therapies are being investigated for the treatment of hepatocellular carcinoma (HOC). The incidence of this malignancy is rising sharply and the vast majority of patients present at advanced stages. Although the earlier dismal results with cytotoxic chemotherapies made way for the development of locoregional therapies that provided improved overall survival, truly personalized therapy will require the selection of phenotypically similar stages of disease and populations, an understanding of the complex molecular and genetic pathways leading to HOC, and a keen understanding of the pathobiology of cirrhosis. Only then will we understand how to offer a particular patient at a specific stage of disease the appropriate therapy to truly prolong survival.

引用

页码：423 / +

页数：20

共 83 条

[1]

Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial [J].